PT  - JOURNAL ARTICLE
AU  - Shen, Mingwang
AU  - Zu, Jian
AU  - Fairley, Christopher K.
AU  - Pagán, José A.
AU  - An, Li
AU  - Du, Zhanwei
AU  - Guo, Yuming
AU  - Rong, Libin
AU  - Xiao, Yanni
AU  - Zhuang, Guihua
AU  - Li, Yan
AU  - Zhang, Lei
TI  - Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use
AID  - 10.1101/2020.10.28.20221234
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.28.20221234
4099  - http://medrxiv.org/content/early/2020/10/30/2020.10.28.20221234.short
4100  - http://medrxiv.org/content/early/2020/10/30/2020.10.28.20221234.full
AB  - Background Multiple candidates of COVID-19 vaccines have entered Phase III clinical trials in the United States (US). There is growing optimism that social distancing restrictions and face mask requirements could be eased with widespread vaccine adoption soon.Methods We developed a dynamic compartmental model of COVID-19 transmission for the four most severely affected states (New York, Texas, Florida, and California). We evaluated the vaccine effectiveness and coverage required to suppress the COVID-19 epidemic in scenarios when social contact was to return to pre-pandemic levels and face mask use was reduced. Daily and cumulative COVID-19 infection and death cases were obtained from the Johns Hopkins University Coronavirus resource center and used for model calibration.Results Without a vaccine, the spread of COVID-19 could be suppressed in these states by maintaining strict social distancing measures and face mask use levels. But relaxing social distancing restrictions to the pre-pandemic level without changing the current face mask use would lead to a new COVID-19 outbreak, resulting in 0.8-4 million infections and 15,000-240,000 deaths across these four states over the next 12 months. In this scenario, introducing a vaccine would partially offset this negative impact even if the vaccine effectiveness and coverage are relatively low. However, if face mask use is reduced by 50%, a vaccine that is only 50% effective (weak vaccine) would require coverage of 55-94% to suppress the epidemic in these states. A vaccine that is 80% effective (moderate vaccine) would only require 32-57% coverage to suppress the epidemic. In contrast, if face mask usage stops completely, a weak vaccine would not suppress the epidemic, and further major outbreaks would occur. A moderate vaccine with coverage of 48-78% or a strong vaccine (100% effective) with coverage of 33-58% would be required to suppress the epidemic. Delaying vaccination rollout for 1-2 months would not substantially alter the epidemic trend if the current interventions are maintained.Conclusions The degree to which the US population can relax social distancing restrictions and face mask use will depend greatly on the effectiveness and coverage of a potential COVID-19 vaccine if future epidemics are to be prevented. Only a highly effective vaccine will enable the US population to return to life as it was before the pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Natural Science Foundation of China (81950410639 (LZ), 11801435 (MS), 11631012 (YX)); Outstanding Young Scholars Support Program (3111500001(LZ)); Xi’an Jiaotong University Basic Research and Profession Grant (xtr022019003(LZ), xzy032020032 (LZ)) and Xi’an Jiaotong University Young Scholar Support Grant (YX6J004(LZ)); the Bill & Melinda Gates Foundation (20200344(LZ)); China Postdoctoral Science Foundation (2018M631134, 2020T130095ZX); the Fundamental Research Funds for the Central Universities (xjh012019055, xzy032020026); Natural Science Basic Research Program of Shaanxi Province (2019JQ-187); Xi’an Special Science and Technology Projects on Prevention and Treatment of Novel Coronavirus Penumonia Emergency (20200005YX005); Zhejiang University special scientific research fund for COVID-19 prevention and control (2020XGZX056).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used only publicly available secondary data so ethics approval is not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are publicly available.